SELF SCORED CARDIOVASCULAR DISEASES RISK APPRAISAL

健康风险评估（HRA）越来越多地被用于健康 中心和工作场所，告知人们他们的个人死亡率， 发病风险。然而，最近的研究表明， 关于冠心病的可靠性和有效性有限， 是这个国家的主要死因自我评分的HRA似乎 在预测冠心病风险方面， 仪器，主要是因为人们并不总是知道生理 这些文书所要求的价值，因为它们经常使 错误计算他们的分数在第一阶段， 风险是开发出来的。第一阶段原型版本包含八个 自我报告的主要风险因素。风险预测的风险 心血管疾病（CVD）在12年内使用 根据最近的加速失效时间模型， 心脏病研究。第二阶段的目的是彻底测试 并改进原型仪器。第二阶段分析的目的是 评估风险的心理测量学特性，评估其 患者判断的效用，并确定仪器是否 改变对个人CVD风险的看法。这些结果将被比较 用于其他评估的数据，以确定Risk是否优于 可比产品。 拟定商业应用： 风险将由健康促进组织分配给 提高对心血管疾病危险因素的认识。 据美国心脏协会估计， 每年生产180，000个HRA。这种产品的潜在市场 包括工作场所，社区卫生中心，管理式医疗保健， 组织、公共卫生部门和诊所。

Health risk appraisals (HRA) are being used increasingly by health centers and worksites to inform people of their personal mortality and morbidity risks. However, recent research suggests that many HRAs have limited reliability and validity with respect to coronary heart disease, the leading cause of death in this country. Self-scored HRAs appear to be considerably less accurate in predicting CHD risk than computerized instruments, chiefly because people do not always know the physiologic values required by these instruments and because they frequently make errors computing their scores. During Phase I, a new appraisal named CardioRisk was developed. The Phase I prototype version contains eight major self-reported risk factors. CardioRisk predicts the risk of developing cardiovascular disease (CVD) in a 12-year period using an equation based on recent accelerated failure time models from the Framingham Heart Study. The purpose of Phase II is to thoroughly test and refine the prototype instrument. The Phase II analyses are designed to assess the psychometric properties of CardioRisk, to evaluate its utility as judged by patients, and to determine whether the instrument changes perceptions of personal CVD risk. These results will be compared to data for other appraisals to determine whether CardioRisk outperforms comparable products. PROPOSED COMMERCIAL APPLICATION: CardioRisk would be distributed by health promotion organizations to increase awareness of the risk factors for cardiovascular disease. Estimates from the American Heart Association put the demand for these products at 180,000 HRAs per year. The potential market for this product includes worksites, community health centers, managed health care organizations, public health departments, and clinics.